On Tuesday, Shares of QUALCOMM, Inc (NASDAQ:QCOM), lost -2.53% to $53.88.
Wileyfox has declared it will launch with two, competitive, open market handsets - Swift and Storm. Accessible online only, each handset boasts a Qualcomm® Snapdragon™ processor and will be the first to come pre-loaded with Cyanogen OS 12.1 in EMEA.
Swift will retail at £129 (€179) and Storm at £199 (€279) and will be accessible from September and October respectively. They are both highly customisable and with exceptional data security settings enabled by Cyanogen and Qualcomm’s SecureMSM™ technology. Both are finished in premium materials, such as Swift’s Corning® Gorilla® Glass display, and offer extraordinary value for money.
Built on Android™, the Cyanogen powered experience gives users the freedom to customise their mobile experience from scratch. Privacy control over data shared with apps, full UI customisation and the elimination of bloatware - to free up storage space and processing power - are all central to the groundbreaking OS.
Wileyfox after sales service features market-wide call centres for advice, support and repairs. Both devices will be accessible exclusively online, at wileyfox.com in addition to at leading e-tailers across the region counting Amazon, Ebay, JD, Souq, Expansys and Clove.
Qualcomm Incorporated (QCOM) is a world leader in 3G, 4G and next-generation wireless technologies. Qualcomm Incorporated comprises Qualcomm’s licensing business, QTL, and the vast majority of its patent portfolio. Qualcomm Technologies, Inc., a wholly-owned partner of Qualcomm Incorporated, operates, together with its auxiliaries, substantially all of Qualcomm’s engineering, research and development functions, and substantially all of its products and services businesses, counting its semiconductor business, QCT.
Shares of Kohl’s Corporation (NYSE:KSS), declined -2.46% to $49.19, during its last trading session.
Kohl’s Corporation (KSS), declared it will unveil the LC Lauren Conrad Runway Collection, an exclusive, limited-edition capsule by Lauren Conrad, during a runway show on Wednesday, September 9. As the chic, vintage-inspired designs make their runway debut, customers across the country will have a front row seat via a shoppable livestream on LCRunway.com. The livestream will feature a special peek at the red carpet, catwalk and behind-the-scenes access, in addition to offer viewers the opportunity to purchase pieces from the collection online right away after the runway show.
“Designing and seeing this capsule collection come to life has been an incredible experience. The aesthetic follows the easy, whimsical style of my Kohl’s brand, but we’ve elevated this collection through amazing fabrications, vintage-inspired pieces and intricate detailing,” said Lauren Conrad. “I am excited to launch LC Lauren Conrad Runway to bring these beautiful, feminine pieces to women across the country and kick start fashion’s biggest week.”
Kohl’s Corporation operates department stores in the United States. It offers private label, exclusive, and national brand apparel, footwear, accessories, beauty, and home products to children, men, and women customers. The company also sells its products online at Kohls.com and through mobile devices. As of March 03, 2015, it operated 1,162 department stores in 49 states Kohl’s Corporation was founded in 1962 and is headquartered in Menomonee Falls, Wisconsin.
Finally, Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP), ended its last trade with -1.55% loss, and closed at $1.90.
Corbus Pharmaceuticals Holdings Inc, declared its financial results for the quarter ended June 30, 2015.
The Company also offered an update on its corporate progress and the clinical status for its investigational drug Resunab™, a novel oral drug that resolves chronic inflammation and fibrotic processes. Resunab is presently in a Phase 2 clinical study in skin-predominant dermatomyositis and is planned to commence Phase 2 clinical trials for the treatment of cystic fibrosis (“CF”) and diffuse cutaneous systemic sclerosis (“scleroderma”) during the third quarter.
Corporate Highlights
- Received a $5 million development award from Cystic Fibrosis Foundation for a Phase 2 clinical study in CF;
- Uplisted to The NASDAQ Capital Market and selected for inclusion in the FTSE Russell MicroCap® Index;
- Issued a call notice for the exercise of the remainder of its outstanding investor warrants that could provide up to $6.2 million in gross proceeds in addition the $4.4 million already received for the six months ended June 30, 2015;
- Commenced patient dosing in a Phase 2 clinical study of Resunab for the treatment of skin-predominant dermatomyositis funded by the National Institutes of Health (“NIH”);
- Received U.S. Food and Drug Administration (“FDA”) Orphan Drug Designation for Resunab for the treatment of scleroderma;
- Presented positive preclinical data demonstrating that Resunab resolves lung inflammation, reduces bacterial load, and improves survival in a CFTR-deficient mouse model;
- Received clearance from the FDA to initiate Phase 2 clinical trials with Resunab in 70 adults with CF and in 36 adults with systemic sclerosis; and
- Designated Charles N. Serhan, Ph.D., a leading authority in inflammatory resolution and the first to identify the role of anti-inflammatory cellular mediators, to the Company’s Scientific Advisory Board.
“We have continued to make notable progress advancing our clinical programs for Resunab with the start of patient dosing in our dermatomyositis Phase 2 study, funded by the NIH, in addition to preparing for the launch our Phase 2 studies in CF and systemic sclerosis,” commented Yuval Cohen, Ph.D., Chief Executive Officer of the Company. “We anticipate continued momentum in the near-term with additional clinical, pre-clinical, regulatory and corporate milestones.”
Corbus Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, focuses on the development and commercialization of novel therapeutics to treat rare life-threatening inflammatory and fibrotic diseases.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
